stock decline

Kaskela Law Firm investigates $UP for potential securities violations as shares plummet 75% since September 2025, targeting long-term shareholders.

Oracle's fiscal Q3 revenue surged 22% with cloud sales up 84% and record $553B backlog, yet stock fell 26% YTD over $45-50B capex plans and layoffs. Valuation now attractive at 18x forward earnings.

Medpace Holdings faces $MEDP class action lawsuit after stock plunges 15.9% due to book-to-bill ratio guidance miss: 1.04x actual vs. 1.15x guided.

Vita Coco faces securities law investigation over alleged investor deception regarding Costco risk and operations. Stock fell 11% after March 26 NINGI Research report.

$SOFI tumbled 10.6% in March amid geopolitical tensions and short-seller allegations of accounting irregularities, though recovered 3.9% in early April.

Trump Media shares fell 13.3% in March amid Iran tensions and weak $3.7M revenue against $712M loss, rebounding 3.2% in April as geopolitical pressures eased.

BitGo Holdings ($BTGO) faces securities probe after swinging from $156.6M profit to $14.8M loss, triggering sharp stock decline.

$SNAP rallied 5% on health advertising initiative, then closed down 1.5% as litigation and profitability concerns weighed on investor sentiment.

uniQure stock plunged 49% after FDA disagreement on gene therapy trial design. Investors with losses eligible to join class action lawsuit by April 2026.

e.l.f. Beauty stock fell 34.2% in March due to Iran-related shipping disruptions raising petrochemical costs, then rebounded 5.3% in April following ceasefire announcements.

Eos Energy ($EOSE) faces securities fraud lawsuit after 2025 revenue of $114.2M fell far short of $150-160M guidance due to production delays.

C3.ai shares down 55% over one year following $133M quarterly loss; CEO insider sale adds to concerns despite $621.9M cash position.

TTD shares jumped 3.38% after-hours following a 6.80% regular decline amid executive departures and Publicis audit concerns over fee transparency.

Trip.com faces securities fraud lawsuit following SAMR antitrust investigation into monopolistic practices. Stock declined 19.4% post-disclosure; investors have until May 2026 to join action.

ImmunityBio hit with securities fraud class action following FDA warning letter over misleading Anktiva cancer therapy ads. Stock fell 21% to $7.42.

uniQure faces securities fraud lawsuit after FDA rejection of AMT-130 data triggers 49% stock plunge from $67.69 to $34.29 on November 3, 2025.

Pomerantz LLP investigates $GDDY for potential securities fraud following disappointing 2026 guidance and 14.28% stock decline on February 25, 2026.

Pomerantz LLP investigates $SRE after disappointing earnings: $970M revenue miss, 50-cent guidance cut, 19% stock decline.

Apple shares fell 2.21% April 7 as foldable iPhone engineering challenges emerged, though September launch remains planned. App Store growth softened amid regulatory pressures.

ADMA Biologics faces securities fraud investigation after short report alleges $20% growth claims masked 3% actual revenue decline, triggering 30% stock collapse.